This review delineates the current role of EGFR inhibitors in the treatment of advanced NSCLC according to EGFR and KRAS status of the tumor, strategies to overcome resistance to agents targeting EGFR and also discusses other recently discovered molecular aberration in lung cancer, ALK rearrangement, which is being efficiently targeted with ALK inhibitors. This evidence concerns the gene ALK and lung carcinoma.